Drugs / ADIPOPLUS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00992485 | Nov 2008 → Sep 2009 | intestinal fistula | Anterogen Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01011244 | Feb 2010 → Sep 2011 | intestinal fistula | Anterogen Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADIPOPLUS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01011244 ↗ |
| Modality | Cell therapy | “autologous adipose-derived stem cell” NCT00992485 ↗ |
| Route | Other | “injection of ADIPOPLUS in fistula site” NCT01011244 ↗ |